Izvorni znanstveni članak
Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) Analysis in Patients with Psoriasis before and after 12 Weeks of Etanercept Therapy: A Preliminary Prospective Study
Concetta Potenza
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Gianfranco Raimondi
; Department of Medical and Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy
Riccardo Pampena
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Nicoletta Bernardini
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Giorgio La Viola
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Ersilia Tolino
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Sara Zuber
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Beatrice Scordamaglia
; Department of Medical and Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy
Nevena Skroza
; Department of Medical and Surgical Sciences and Biotechnologies, Division of Dermatology “Daniele Innocenzi”, Sapienza University of Rome, Polo Pontino, Italy
Sažetak
Background The association between psoriasis and cardiovascular diseases is suggested by epidemiological studies. The sub-inflammatory systemic state that characterizes both psoriasis and atherosclerosis has been proposed as the link between these conditions; it cannot, however, explain the increased incidence of sudden cardiac death reported in young patients with severe psoriasis without common cardiovascular risk factors. In a previous study we reported higher levels of autonomic dysregulation in psoriatic patients, concluding that the prevalence of the sympathetic arm over the para-sympathetic one could increase cardiovascular risk.
Objectives To assess the influence of etanercept, an anti-TNFα agent, on the autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors.
Methods Five-minute ECG recordings were collected at rest conditions before and after 12 weeks of therapy with etanercept in 19 young psoriatic patients without cardiovascular risk factors. The Cardiolab CE pocket PC ECG system was used for linear methods of heart rate variability (HRV) analysis.
Results No significant change in HRV analysis parameters was apparent after 12 weeks of etanercept therapy.
Conclusion Our data suggest that treatment with etanercept in patients with moderate-to-severe psoriasis doesn't affect cardiovascular autonomic regulation, and subsequently the cardiovascular risk.
Ključne riječi
etanercept; cardiovascular risk; heart rate variability analysis; psoriasis
Hrčak ID:
165613
URI
Datum izdavanja:
13.9.2016.
Posjeta: 845 *